Japan
Source: Globocan 2020

Summary statistic 2020

<table>
<thead>
<tr>
<th></th>
<th>Males</th>
<th>Females</th>
<th>Both sexes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td>61 753 045</td>
<td>64 723 413</td>
<td>126 476 458</td>
</tr>
<tr>
<td>Number of new cases</td>
<td>599 243</td>
<td>429 415</td>
<td>1 028 658</td>
</tr>
<tr>
<td>Age-standardized incidence rate (World)</td>
<td>328.1</td>
<td>253.8</td>
<td>285.1</td>
</tr>
<tr>
<td>Risk of developing cancer before the age of 75 years (%)</td>
<td>32.3</td>
<td>24.1</td>
<td>28.1</td>
</tr>
<tr>
<td>Number of deaths</td>
<td>239 505</td>
<td>180 619</td>
<td>420 124</td>
</tr>
<tr>
<td>Age-standardized mortality rate (World)</td>
<td>105.6</td>
<td>62.6</td>
<td>81.5</td>
</tr>
<tr>
<td>Risk of dying from cancer before the age of 75 years (%)</td>
<td>10.2</td>
<td>5.9</td>
<td>8.0</td>
</tr>
<tr>
<td>5-year prevalent cases</td>
<td>1 514 292</td>
<td>1 196 436</td>
<td>2 710 728</td>
</tr>
</tbody>
</table>

Top 5 most frequent cancers excluding non-melanoma skin cancer (ranked by cases)

- Prostate
- Stomach
- Colorectum
- Lung
- Pancreas

Geography
Numbers at a glance

Total population

126 476 458

Number of new cases

1 028 658

Number of deaths

420 124

Number of prevalent cases (5-year)

2 710 728

Data source and methods

Incidence
Country-specific data source: Aichi Cancer Registry, Fukui Cancer Registry, Hiroshima Cancer Registry, Miyagi Cancer Registry, Nagasaki Cancer Registry, Niigata Cancer Registry, Osaka Cancer Registry, Tochigi Cancer Registry, Yamagata Cancer Registry
Method: Estimated from national mortality estimates by modelling, using mortality:incidence ratios derived from country-specific cancer registry data

Mortality
Country-specific data source: National (WHO)
Method: National rates projected to 2020

Prevalence
Computed using sex-; site- and age-specific incidence to 1-;3- and 5-year prevalence ratios from Nordic countries for the period (2006-2015), and scaled using Human Development Index (HDI) ratios.
Incidence, Mortality and Prevalence by cancer site

<table>
<thead>
<tr>
<th>Cancer</th>
<th>New cases</th>
<th>Deaths</th>
<th>5-year prevalence (all ages)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number</td>
<td>Rank (%)</td>
<td>Cum.risk</td>
</tr>
<tr>
<td>Lung</td>
<td>138 322</td>
<td>1</td>
<td>13.5</td>
</tr>
<tr>
<td>Stomach</td>
<td>138 470</td>
<td>2</td>
<td>13.5</td>
</tr>
<tr>
<td>Prostate</td>
<td>106 139</td>
<td>3</td>
<td>10.3</td>
</tr>
<tr>
<td>Colon</td>
<td>96 781</td>
<td>4</td>
<td>9.4</td>
</tr>
<tr>
<td>Breast</td>
<td>92 024</td>
<td>5</td>
<td>8.9</td>
</tr>
<tr>
<td>Rectum</td>
<td>50 668</td>
<td>6</td>
<td>4.9</td>
</tr>
<tr>
<td>Liver</td>
<td>45 663</td>
<td>7</td>
<td>4.4</td>
</tr>
<tr>
<td>Pancreas</td>
<td>44 307</td>
<td>8</td>
<td>4.3</td>
</tr>
<tr>
<td>Bladder</td>
<td>36 957</td>
<td>9</td>
<td>3.6</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td>33 000</td>
<td>10</td>
<td>3.2</td>
</tr>
<tr>
<td>Oesophagus</td>
<td>26 262</td>
<td>11</td>
<td>2.6</td>
</tr>
<tr>
<td>Kidney</td>
<td>25 145</td>
<td>12</td>
<td>2.4</td>
</tr>
<tr>
<td>Thyroid</td>
<td>18 087</td>
<td>13</td>
<td>1.8</td>
</tr>
<tr>
<td>Corpus uteri</td>
<td>17 850</td>
<td>14</td>
<td>1.7</td>
</tr>
<tr>
<td>Leukaemia</td>
<td>13 667</td>
<td>15</td>
<td>1.1</td>
</tr>
<tr>
<td>Cervix uteri</td>
<td>12 785</td>
<td>16</td>
<td>1.2</td>
</tr>
<tr>
<td>Lip, oral cavity</td>
<td>11 210</td>
<td>17</td>
<td>1.1</td>
</tr>
<tr>
<td>Ovary</td>
<td>10 964</td>
<td>18</td>
<td>1.1</td>
</tr>
<tr>
<td>Gallbladder</td>
<td>9 734</td>
<td>19</td>
<td>0.95</td>
</tr>
<tr>
<td>Multiple myeloma</td>
<td>7 234</td>
<td>20</td>
<td>0.70</td>
</tr>
<tr>
<td>Brain, central nervous system</td>
<td>5 517</td>
<td>21</td>
<td>0.54</td>
</tr>
<tr>
<td>Larynx</td>
<td>5 115</td>
<td>22</td>
<td>0.50</td>
</tr>
<tr>
<td>Hypopharynx</td>
<td>4 397</td>
<td>23</td>
<td>0.43</td>
</tr>
<tr>
<td>Oropharynx</td>
<td>2 528</td>
<td>24</td>
<td>0.25</td>
</tr>
<tr>
<td>Testis</td>
<td>2 458</td>
<td>25</td>
<td>0.24</td>
</tr>
<tr>
<td>Mesothelioma</td>
<td>2 283</td>
<td>26</td>
<td>0.22</td>
</tr>
<tr>
<td>Hodgkin lymphoma</td>
<td>1 723</td>
<td>27</td>
<td>0.17</td>
</tr>
<tr>
<td>Sella/sella gland</td>
<td>1 642</td>
<td>28</td>
<td>0.16</td>
</tr>
<tr>
<td>Melanoma of skin</td>
<td>1 514</td>
<td>29</td>
<td>0.15</td>
</tr>
<tr>
<td>Vulva</td>
<td>1 283</td>
<td>30</td>
<td>0.12</td>
</tr>
<tr>
<td>Testis</td>
<td>1 056</td>
<td>31</td>
<td>0.10</td>
</tr>
<tr>
<td>Nasopharynx</td>
<td>843</td>
<td>32</td>
<td>0.08</td>
</tr>
<tr>
<td>Penis</td>
<td>512</td>
<td>33</td>
<td>0.05</td>
</tr>
<tr>
<td>Vagina</td>
<td>390</td>
<td>34</td>
<td>0.04</td>
</tr>
<tr>
<td>Kaposi sarcoma</td>
<td>47</td>
<td>35</td>
<td>0.00</td>
</tr>
<tr>
<td>All cancer sites</td>
<td>1 026 058</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

**Age-standardized (World) incidence rates per sex, top 10 cancers**

- **Male**: High incidence in colorectal, breast, and lung cancers.
- **Female**: High incidence in breast, prostate, and colorectal cancers.

**Age-standardized (World) incidence and mortality rates, top 10 cancers**

- **Incidence**:
  - Highest in colorectal, lung, and prostate cancers.
- **Mortality**:
  - Highest in colorectal, lung, and prostate cancers.